Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 8, 2011, Pages 973-977

  Solomon, M ^a   Pavlotsky, F ^a   Leshem, E ^a   Ephros, M ^b,c   Trau, H ^a   Schwartz, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

cutaneous leishmaniasis; Leishmania tropica; liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE; HYDROCORTISONE; KETOCONAZOLE; LESHCUTAN; PAROMOMYCIN; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ADULT; ANGIONEUROTIC EDEMA; ANTIMICROBIAL THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CRYOTHERAPY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; ISRAEL; KIDNEY DYSFUNCTION; LEISHMANIA TROPICA; MALE; NAUSEA AND VOMITING; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT FAILURE;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISRAEL; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960253290     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03908.x     Document Type: Article

References (30)

1. Jaffe CL, Baneth G, Abdeen ZA, et al. Leishmaniasis in Israel and the Palestinian Authority. Trends Parasitol 2004; 20: 328-332. (Pubitemid 38749076)
2. Schlein Y, Warburg A, Schnur LF, et al. Leishmaniasis in Israel: reservoir hosts, sandfly vectors and leishmanial strains in the Negev, Central Arava and along the Dead Sea. Trans R Soc Trop Med Hyg 1984; 78: 480-484.
3. Anis E, Leventhal A, Elkana Y, et al. Cutaneous leishmaniasis in Israel in the era of changing environment. Public Health Rev 2001; 29: 37-47. (Pubitemid 34019278)
4. Klaus S, Frankenburg S,. Cutaneous leishmaniasis in the Middle East. Clin Dermatol 1999; 17: 137-141; discussion 5-6. (Pubitemid 29497863)
5. Jacobson RL, Eisenberger CL, Svobodova M, et al. Outbreak of cutaneous leishmaniasis in northern Israel. J Infect Dis 2003; 188: 1065-1073. (Pubitemid 37268259)
6. Hepburn NC,. Cutaneous leishmaniasis. Clin Exp Dermatol 2000; 25: 363-370.
7. Momeni AZ, Aminjavaheri M,. Treatment of recurrent cutaneous Leishmaniasis. Int J Dermatol 1995; 34: 129-133.
8. Moskowitz PF, Kurban AK,. Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Clin Dermatol 1999; 17: 305-315. (Pubitemid 29497895)
9. Magill AJ, Grogl M, Gasser RA, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328: 1383-1387. (Pubitemid 23131391)
10. Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol 2005; 53: 810-815. (Pubitemid 41501366)
11. Herwaldt BL, Berman JD,. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.
12. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-895. (Pubitemid 34984637)
13. Herwaldt BL,. Leishmaniasis. Lancet 1999; 354: 1191-1199. (Pubitemid 29460458)
14. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158-166. (Pubitemid 38239944)
15. Davidson RN,. Practical guide for the treatment of leishmaniasis. Drugs 1998; 56: 1009-1018. (Pubitemid 29010219)
16. Grevelink SA, Lerner EA,. Leishmaniasis. J Am Acad Dermatol 1996; 34 (2 Pt 1): 257-272. (Pubitemid 26063997)
17. el-On J, Halevy S, Grunwald MH, et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27 (2 Pt 1): 227-231.
18. el-On J, Weinrauch L, Livshin R, et al. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride. Br Med J (Clin Res Ed) 1985; 291: 704-705. (Pubitemid 15238029)
19. Ozgoztasi O, Baydar I,. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol 1997; 36: 61-63. (Pubitemid 27139758)
20. Solomon M, Baum S, Barzilai A, et al. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol 2009; 23: 1189-1192.
21. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998; 27: 1457-1464. (Pubitemid 29242421)
22. Lawn SD, Armstrong M, Chilton D, et al. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100: 264-269. (Pubitemid 43091825)
23. Keynan Y, Larios OE, Wiseman MC, et al. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 2008; 19: 394-396.
24. Minodier P, Retornaz K, Horelt A, et al. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam Clin Pharmacol 2003; 17: 183-188. (Pubitemid 36513209)
25. Musa AM, Khalil EA, Mahgoub FA, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005; 99: 563-569. (Pubitemid 41215648)
26. Schwartz E,. Leishmaniasis. In, Schwartz E, ed. Tropical Diseases in Travelers, 1st edn. Wiley-Blackwell, UK, 2009: 13-27.
27. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56: 612-616. (Pubitemid 46400168)
28. Davidson RN, di Martino L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938-943. (Pubitemid 26260592)
29. Yardley V, Croft SL,. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41: 752-756. (Pubitemid 27150525)
30. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504-512.